These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 8531860)

  • 1. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
    Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
    Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
    Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hearing loss caused by high dose carboplatin therapy].
    Lautermann J; Adamczyk M; ten Cate WJ; Kloke O
    Laryngorhinootologie; 1998 Feb; 77(2):82-4. PubMed ID: 9555700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma.
    Parsons SK; Neault MW; Lehmann LE; Brennan LL; Eickhoff CE; Kretschmar CS; Diller LR
    Bone Marrow Transplant; 1998 Oct; 22(7):669-74. PubMed ID: 9818694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
    Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
    Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors.
    Gardner SL; Asgharzadeh S; Green A; Horn B; McCowage G; Finlay J
    Pediatr Blood Cancer; 2008 Aug; 51(2):235-40. PubMed ID: 18381756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incidence of hearing impairment after successful treatment of neuroblastoma.
    Simon T; Hero B; Dupuis W; Selle B; Berthold F
    Klin Padiatr; 2002; 214(4):149-52. PubMed ID: 12165893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue.
    Zacharoulis S; Levy A; Chi SN; Gardner S; Rosenblum M; Miller DC; Dunkel I; Diez B; Sposto R; Ji L; Asgharzadeh S; Hukin J; Belasco J; Dubowy R; Kellie S; Termuhlen A; Finlay J
    Pediatr Blood Cancer; 2007 Jul; 49(1):34-40. PubMed ID: 16874765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.
    Dhooge I; Dhooge C; Geukens S; De Clerck B; De Vel E; Vinck BM
    Int J Audiol; 2006 Jun; 45(6):337-43. PubMed ID: 16777780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ototoxicity of cisplatin in children with malignant diseases].
    Hadjilaskari P; Fengler R; Hartmann R; Henze G
    Klin Padiatr; 1989; 201(4):316-21. PubMed ID: 2779137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brainstem primitive neuroectodermal tumors (bstPNET): results of treatment with intensive induction chemotherapy followed by consolidative chemotherapy with autologous hematopoietic cell rescue.
    Fangusaro JR; Jubran RF; Allen J; Gardner S; Dunkel IJ; Rosenblum M; Atlas MP; Gonzalez-Gomez I; Miller D; Finlay JL
    Pediatr Blood Cancer; 2008 Mar; 50(3):715-7. PubMed ID: 17009232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children.
    Macdonald MR; Harrison RV; Wake M; Bliss B; Macdonald RE
    J Otolaryngol; 1994 Jun; 23(3):151-9. PubMed ID: 8064951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience.
    Fangusaro J; Finlay J; Sposto R; Ji L; Saly M; Zacharoulis S; Asgharzadeh S; Abromowitch M; Olshefski R; Halpern S; Dubowy R; Comito M; Diez B; Kellie S; Hukin J; Rosenblum M; Dunkel I; Miller DC; Allen J; Gardner S
    Pediatr Blood Cancer; 2008 Feb; 50(2):312-8. PubMed ID: 17668858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.
    Dahlborg SA; Petrillo A; Crossen JR; Roman-Goldstein S; Doolittle ND; Fuller KH; Neuwelt EA
    Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy.
    Lambert MP; Shields C; Meadows AT
    Pediatr Blood Cancer; 2008 Feb; 50(2):223-6. PubMed ID: 17278120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol.
    Ilveskoski I; Saarinen UM; Wiklund T; Perkkiö M; Salmi TT; Lanning M; Mäkipernaa A; Pihko H
    Med Pediatr Oncol; 1996 Jul; 27(1):26-31. PubMed ID: 8614387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monitoring hearing during ototoxic cisplatin therapy].
    Kluba J; Kluba U; von Specht H; Mittler U
    Padiatr Grenzgeb; 1990; 29(1):19-23. PubMed ID: 2342815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
    Massimino M; Gandola L; Spreafico F; Biassoni V; Luksch R; Collini P; Solero CN; Simonetti F; Pignoli E; Cefalo G; Poggi G; Modena P; Mariani L; Potepan P; Podda M; Casanova M; Pecori E; Acerno S; Ferrari A; Terenziani M; Meazza C; Polastri D; Ravagnani F; Fossati-Bellani F
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1358-63. PubMed ID: 19019566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors.
    Broun ER; Nichols CR; Mandanas R; Salzman D; Turns M; Hromas R; Cornetta K; Einhorn LH
    Bone Marrow Transplant; 1995 Sep; 16(3):353-8. PubMed ID: 8535306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.